| Laura Berzins Optometrist Pc | |
|
164 Northern Blvd, Great Neck, NY 11021-4322 | |
| (516) 439-4951 | |
| Not Available |
| Full Name | Laura Berzins Optometrist Pc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 164 Northern Blvd, Great Neck, New York |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326622804 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Provider Name | Laura Berzins |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1578810594 PECOS PAC ID: 1254577257 Enrollment ID: I20130417000657 |
News Archive
Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.
Glaucoma, the second leading cause of blindness, usually stems from elevated eye pressure, which in turn damages and destroys specialized neurons in the eye known as retinal ganglion cells. To better understand these cellular changes and how they influence the progression and severity of glaucoma, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute turned to a mouse model of the disease.
Dr Rafael Yáñez-Muñoz, from the School of Biological Sciences at Royal Holloway, University of London, is leading a team of researchers working to develop a novel treatment for spinal cord injury - which leaves sufferers with devastating, life-long effects including paralysis.
HealthLeaders-InterStudy and Fingertip Formulary find that 70 percent of surveyed pharmacy directors expect to cover Pfizer's tanezumab if it is approved for the treatment of chronic pain. Tanezumab, which is expected to be the first biologic approved for chronic pain and is administered intravenously under medical supervision, will likely be covered as a medical benefit rather than a pharmacy benefit according to surveyed pharmacy directors.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Berzins Optometrist Pc 164 Northern Blvd, Great Neck, NY 11021-4322 Ph: (516) 439-4951 | Laura Berzins Optometrist Pc 164 Northern Blvd, Great Neck, NY 11021-4322 Ph: (516) 439-4951 |
News Archive
Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.
Glaucoma, the second leading cause of blindness, usually stems from elevated eye pressure, which in turn damages and destroys specialized neurons in the eye known as retinal ganglion cells. To better understand these cellular changes and how they influence the progression and severity of glaucoma, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute turned to a mouse model of the disease.
Dr Rafael Yáñez-Muñoz, from the School of Biological Sciences at Royal Holloway, University of London, is leading a team of researchers working to develop a novel treatment for spinal cord injury - which leaves sufferers with devastating, life-long effects including paralysis.
HealthLeaders-InterStudy and Fingertip Formulary find that 70 percent of surveyed pharmacy directors expect to cover Pfizer's tanezumab if it is approved for the treatment of chronic pain. Tanezumab, which is expected to be the first biologic approved for chronic pain and is administered intravenously under medical supervision, will likely be covered as a medical benefit rather than a pharmacy benefit according to surveyed pharmacy directors.
› Verified 7 days ago
Dr. Eleonora Tamayeva, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 146 Middle Neck Rd, Great Neck, NY 11021 Phone: 516-466-3874 | |
Dr. Konstantinos Booras, O.D., F.A.A.O. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 505 Northern Blvd, Suite 313, Great Neck, NY 11021 Phone: 516-472-7310 Fax: 516-368-3862 | |
Dr. Dina Franklin, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 218 Lakeville Rd, Great Neck, NY 11020 Phone: 718-502-9821 | |
Dr. Farnoush Shahkohi, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 14 Morris Ln, Great Neck, NY 11024 Phone: 516-707-5145 Fax: 347-887-5000 | |
Citywide Eye Care Optometry Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 107 Middle Neck Rd, Great Neck, NY 11021 Phone: 718-357-4884 | |
Dr. Behnam Cohenmehr, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 12 Bond St Apt 4a, Great Neck, NY 11021 Phone: 516-902-4444 | |
Dr. Erica Meltzer, OD Optometrist Medicare: Medicare Enrolled Practice Location: 80 Middle Neck Rd, Great Neck, NY 11021 Phone: 516-487-3074 Fax: 516-487-2581 |